Our work on dual BTK and BCL2 inhibition in marginal zone lymphoma, using the new BTK degrader BGB-16673 and the BCL2 inhibitor sonrotoclax, is now available on @biorxivpreprint.bsky.social @iorbellinzona.bsky.social @usi.ch www.biorxiv.org/content/10.1...

#IORnews 🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer. Learn more: ior.usi.ch/events-news/...

Yesterday we had our first 19-ICML Local Organising Committee meeting — the behind-the-scenes work for the next edition has officially begun! 💥 @frbertoni.bsky.social #19ICML #ICML #lymphoma #CLL #myeloma #lymssm

Here are the 4 abstracts exploring novel therapeutics for patients with marginal zone lymphomas we're presenting at the #Targets25: -Epigenetic vulnerabilities in marginal zone lymphoma doi.org/10.1158/1535... @iorbellinzona.bsky.social @usi.ch

#IORnews An international study conducted by the IOR Experimental Hematology Laboratory, led by Prof. Davide Rossi, offers a new perspective on the genetics of classical Hodgkin lymphoma. Learn more: ior.usi.ch/events-news/...

Our letter by Nicolas Munz on in vitro lymphoma models for polatuzumab vedotin is now online in the British Journal of Haematology. Thanks to everybody at @iorbellinzona.bsky.social @usi.ch @snsf.ch onlinelibrary.wiley.com/doi/10.1111/...

The review article, written in collaboration with Camille Laurent, on the biology of marginal zone lymphomas is now published in Blood. @iorbellinzona.bsky.social @usi.ch Università della Svizzera italiana @snsf.ch doi.org/10.1182/bloo...

“Recent Advances in Treating Diffuse Large B-Cell Lymphoma “ by Jim Armitage ascopost.com/issues/june-...

A work, by Filippo Spriano in our lab, exploring the mechanisms of resistance to TK216, a molecule that targets ETS factors, is now available in bioRxiv www.biorxiv.org/content/10.1...

Our collaborative work with Sebastian Patzke and Jostein Dahle on the CD37 targetting radioimmunoconjugated antibody 177Lu-lilotomab satetraxetan (Betalutin) is out in the British Journal of Haematology. onlinelibrary.wiley.com/doi/10.1111/...

Thanks to a collaboration with Francesco Buonocore and Maria Luisa Mangoni, we explored antimicrobial peptides (AMPs) in marginal zone lymphomas. The initial work by Filippo Spriano and others at the @iorbellinzona.bsky.social, is now available. @usi.ch www.biorxiv.org/content/10.1...

A screening of the Irish marine biorepository identified a new bryostatin analog active in lymphomas. Nice collaboration with Olivier Thomas, his team, Filippo Spriano and other members of our @iorbellinzona.bsky.social lab. @usi.ch @sib.swiss chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...

Registrations are open for the next LyFE - Lymphoma Forum of Excellence «What's new in lymphoid neoplasias?», Bellinzona, Switzerland, February 2026 www.lymphomaforum.ch

#IORnews A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL. Learn more: tinyurl.com/ytybcbr8

Project Hail Mary by Andy Weir: a very nice reading! en.wikipedia.org/wiki/Project...

Elliott Smith - www.udiscovermusic.com/stories/best...

📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx. #DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines 🔗 buff.ly/2ZYJc2c

new ESMO Lymphoma Clinical Practice Guideline for diagnosis, treatment and follow-up www.esmo.org/guidelines/e...

A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience. If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome. pls share 🙏

Here is a curated list of #patienteducation resources in Simplified or Traditional #Chinese on #health- or #cancer- related topics available from US, UK, EU, Australia, Singapore, Hong Kong, Taiwan, and India. We are curating support groups in US - input needed blogs.hear2care.org/patientresou...

“The Best Song From Every David #Bowie Album” by Ultimate Classic Rock: I largely agree but I would have chosen differently from some album. Difficult sometime to select only one song. Bowie is still the best one. ultimateclassicrock.com/david-bowie-...

Sonic Youth’s Daydream Nation amazed when they came out and I still listen to it. Wonderful album and band. www.udiscovermusic.com/stories/soni...

Slash’s 10 greatest riffs ever faroutmagazine.co.uk/slash-10-gre...

Circulating miRNA in lymphomas. The work by Giulia Regazzo from Maria Giulio Rizzo’s group in Rome is out in the BJH. Glad to have contributed. @iorbellinzona.bsky.social @usi.ch onlinelibrary.wiley.com/doi/10.1111/...

Our very interesting work on CXCR4 inhibition to increase the activity of therapies in B-cell lymphomas is now available in bioRxiv. Thanks to Laura Barnabei, Alberto Arribas, and all the contributors. @iorbellinzona.bsky.social @sib.swiss @usi.ch www.biorxiv.org/content/10.1...

Registration is open for the International Prostate Cancer Symposium (IPCS) 28–29 April 2026 – Lugano, Switzerland Held just before APCCC 2026, IPCS is your chance to explore next-gen treatments & breakthrough research in prostate cancer care. 🔗Register now: apccc.org

#IORjobs IOR invites applications from outstanding candidates interested in applying for the SNSF Ambizione and Marie Skłodowska-Curie Actions (MSCA) and EMBO fellowships. ⏳ IOR internal deadline: 3 August 2025 ➡️ Details & application procedure: shorturl.at/caVdu

“The combination of glofitamab with R-CHOP or Pola-R-CHP is deliverable and results in high rates of durable response in this population of younger patients with high-burden supporting its ongoing exploration as a [first-line] treatment “ ascopubs.org/doi/10.1200/... ascopost.com/news/july-20...

"Despite limitations of retrospective design and heterogeneity across BTKi agents, these results suggest that BTKi maintenance may redefine long-term management in PCNSL. " www.rarediseaseadvisor.com/news/btk-inh...

Very glad to be part of the faculty on the new ESO Comprehensive Online Course on Oncology Research and Clinical Trials. www.e-eso.net/courses/25RCT

"T-Cell Redirecting Strategies in Large B-Cell Lymphoma and Follicular Lymphoma" by Gloria Iacoboni @icmlugano.bsky.social onlinelibrary.wiley.com/doi/abs/10.1...

The results showing the benefit of combining the non-ATP competitive Pi3Kδ inhibitor roginolisib with venetoclax in lymphoid tumors are out in Haematologica. A collaboration of @iorbellinzona.bsky.social, Jennifer Brown’s group and iOnctura colleagues. haematologica.org/newsletter/v...

A work on new semi-synthetic flavonoid derivatives with anti-tumor activity in lymphoma models is out in eJHaem. Thanks to Eugenio Gaudio, Paulina Biniecka, and Dan Stoicescu for involving us. @iorbellinzona.bsky.social doi.org/10.1002/jha2...

Won Seog Kim's talk on PTCL is about to start. @icmlugano.bsky.social onlinelibrary.wiley.com/doi/10.1002/...

AACR CEO Margaret Foti and #18ICML Organizing Committee Chair Francesco Bertoni co-chaired the AACR-ICML Joint Session on "The Role of Artificial Intelligence in Oncology" today at the International Conference on Malignant Lymphoma in Lugano. @frbertoni.bsky.social @icmlugano.bsky.social ‬

Our collaborative work exploring the metabolism-targeting agent KAT/3BP as single and in combination in B-cell lymphoma models is now out in Cancers. Thanks to Chiara Tarantelli, Filippo Spriano, and everybody else who [email protected] www.mdpi.com/2072-6694/17...

Simone Ferrero's talk on MCL biomarkers at @icmlugano.bsky.social

Steven Treon's talk on WM at the @icmlugano.bsky.social

Sonali Smith's talk now at the @icmlugano.bsky.social @womeninlymphoma.bsky.social

“Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL”

#IORjobs Open PhD Position! Join Arianna Baggiolini @ariannabaggiolini.bsky.social ’s Lab to work on human pluripotent stem cell (hPSC)-based models of the peripheral nervous system and disease. Info and application: ior.usi.ch/events-news/...

I agree with this rank!

Airolo-Andermatt in funivia: idea per il futuro

Sustained Efficacy of Zanubrutinib in Chronic Lymphocytic Leukemia www.onclive.com/view/long-te...

The @ascocancer.bsky.social Ed Book is the highest-quality, peer-reviewed, FREE #oncology #MedEd ever. Whether or not you’re at #ASCO25, don’t miss this resource, #OncSky #MedSky, #MedStudentSky! Drop a 📌 in the comments to bookmark the link for later. ascopubs.org/toc/edbk/cur... #OncoAlert

📣 Join us! Were looking for a PhD student to join our lab and work on human pluripotent stem cell (hPSC)-based models of the peripheral nervous system and disease. Come be part of our supportive and dynamic lab family in the beautiful Bellinzona, Southern Switzerland 🇨🇭☀️⛰️ ior.usi.ch/events-news/...

Systematic review of low-dose anti-PD1 in Hodgkin lymphoma indicates comparable ORR, CR rates & toxicity to full dose aPD1 ascopubs.org/doi/10.1200/... Important open access publication @ascocancer.bsky.social JCO Global Oncology: Decrease costs and increase global health equity through aPD1 access?

🚨 We're hiring an Administrative Medical Liaison Officer to support the coordination of our scientific activities! This key role involves working closely with our Medical Representative to ensure seamless operations. Apply now: www.eortc.org/job/medical-... #Jobs #Vacancy #Oncology

ASCO educational article on liquid biopsy ascopubs.org/doi/pdf/10.1...